119 related articles for article (PubMed ID: 23284857)
1. Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings.
Curtis AJ; Marshall CS; Spelman T; Greig J; Elliot JH; Shanks L; Du Cros P; Casas EC; Da Fonseca MS; O'Brien DP
PLoS One; 2012; 7(12):e52019. PubMed ID: 23284857
[TBL] [Abstract][Full Text] [Related]
2. Impact of HIV-associated conditions on mortality in people commencing anti-retroviral therapy in resource limited settings.
Marshall CS; Curtis AJ; Spelman T; O'Brien DP; Greig J; Shanks L; du Cros P; Casas EC; da Fonseca MS; Athan E; Elliott JH
PLoS One; 2013; 8(7):e68445. PubMed ID: 23935870
[TBL] [Abstract][Full Text] [Related]
3. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy.
O'Brien DP; Sauvageot D; Zachariah R; Humblet P;
AIDS; 2006 Oct; 20(15):1955-60. PubMed ID: 16988517
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for mortality during antiretroviral therapy in older populations in resource-limited settings.
O'Brien D; Spelman T; Greig J; McMahon J; Ssonko C; Casas E; Mesic A; Du Cros P; Ford N
J Int AIDS Soc; 2016; 19(1):20665. PubMed ID: 26782169
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration.
Leroy V; Malateste K; Rabie H; Lumbiganon P; Ayaya S; Dicko F; Davies MA; Kariminia A; Wools-Kaloustian K; Aka E; Phiri S; Aurpibul L; Yiannoutsos C; Signaté-Sy H; Mofenson L; Dabis F;
J Acquir Immune Defic Syndr; 2013 Feb; 62(2):208-19. PubMed ID: 23187940
[TBL] [Abstract][Full Text] [Related]
6. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.
Pujades-Rodríguez M; Balkan S; Arnould L; Brinkhof MA; Calmy A;
JAMA; 2010 Jul; 304(3):303-12. PubMed ID: 20639564
[TBL] [Abstract][Full Text] [Related]
7. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.
Naidoo K; Yende-Zuma N; Padayatchi N; Naidoo K; Jithoo N; Nair G; Bamber S; Gengiah S; El-Sadr WM; Friedland G; Abdool Karim S
Ann Intern Med; 2012 Sep; 157(5):313-24. PubMed ID: 22944873
[TBL] [Abstract][Full Text] [Related]
8. Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort study.
Rohner E; Valeri F; Maskew M; Prozesky H; Rabie H; Garone D; Dickinson D; Chimbetete C; Lumano-Mulenga P; Sikazwe I; Wyss N; Clough-Gorr KM; Egger M; Chi BH; Bohlius J
J Acquir Immune Defic Syndr; 2014 Dec; 67(5):547-54. PubMed ID: 25393941
[TBL] [Abstract][Full Text] [Related]
9. Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study.
Katz IT; Kaplan R; Fitzmaurice G; Leone D; Bangsberg DR; Bekker LG; Orrell C
PLoS Med; 2017 Nov; 14(11):e1002434. PubMed ID: 29136014
[TBL] [Abstract][Full Text] [Related]
10. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
[TBL] [Abstract][Full Text] [Related]
11. Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings.
Forster M; Bailey C; Brinkhof MW; Graber C; Boulle A; Spohr M; Balestre E; May M; Keiser O; Jahn A; Egger M;
Bull World Health Organ; 2008 Dec; 86(12):939-47. PubMed ID: 19142294
[TBL] [Abstract][Full Text] [Related]
12. Contemporary disengagement from antiretroviral therapy in Khayelitsha, South Africa: A cohort study.
Kaplan SR; Oosthuizen C; Stinson K; Little F; Euvrard J; Schomaker M; Osler M; Hilderbrand K; Boulle A; Meintjes G
PLoS Med; 2017 Nov; 14(11):e1002407. PubMed ID: 29112692
[TBL] [Abstract][Full Text] [Related]
13. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control.
Lawn SD; Myer L; Bekker LG; Wood R
AIDS; 2006 Aug; 20(12):1605-12. PubMed ID: 16868441
[TBL] [Abstract][Full Text] [Related]
14. Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.
Gabillard D; Lewden C; Ndoye I; Moh R; Segeral O; Tonwe-Gold B; Etard JF; Pagnaroat M; Fournier-Nicolle I; Eholié S; Konate I; Minga A; Mpoudi-Ngole E; Koulla-Shiro S; Zannou DM; Anglaret X; Laurent C;
J Acquir Immune Defic Syndr; 2013 Apr; 62(5):555-61. PubMed ID: 23274931
[TBL] [Abstract][Full Text] [Related]
15. Time to initiation of antiretroviral therapy among patients who Are ART eligible in Rwanda: improvement over time.
Teasdale CA; Wang C; Francois U; Ndahimana Jd; Vincent M; Sahabo R; El-Sadr WM; Abrams EJ;
J Acquir Immune Defic Syndr; 2015 Mar; 68(3):314-21. PubMed ID: 25415291
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of antiretroviral therapy over a 10-year period of expansion: a multicohort analysis of African and Asian HIV programs.
Grimsrud A; Balkan S; Casas EC; Lujan J; Van Cutsem G; Poulet E; Myer L; Pujades-Rodriguez M
J Acquir Immune Defic Syndr; 2014 Oct; 67(2):e55-66. PubMed ID: 24977472
[TBL] [Abstract][Full Text] [Related]
17. Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children.
Edmonds A; Lusiama J; Napravnik S; Kitetele F; Van Rie A; Behets F
Int J Epidemiol; 2009 Dec; 38(6):1612-21. PubMed ID: 19448046
[TBL] [Abstract][Full Text] [Related]
18. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
[TBL] [Abstract][Full Text] [Related]
19. Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women.
Kourtis AP; Wiener J; King CC; Heffron R; Mugo NR; Nanda K; Pyra M; Donnell D; Celum C; Lingappa JR; Baeten JM;
J Acquir Immune Defic Syndr; 2017 Jan; 74(1):38-43. PubMed ID: 27787340
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of HIV-Infected Children at Enrollment into Care and at Antiretroviral Therapy Initiation in Central Africa.
Adedimeji A; Edmonds A; Hoover D; Shi Q; Sinayobye JD; Nduwimana M; Lelo P; Nash D; Anastos K; Yotebieng M
PLoS One; 2017; 12(1):e0169871. PubMed ID: 28081230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
